Securian Asset Management Inc. Trims Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Securian Asset Management Inc. reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,618 shares of the biopharmaceutical company’s stock after selling 232 shares during the period. Securian Asset Management Inc.’s holdings in Halozyme Therapeutics were worth $460,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of HALO. GSA Capital Partners LLP acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $217,000. CIBC Asset Management Inc purchased a new position in Halozyme Therapeutics in the third quarter worth approximately $211,000. Natixis Advisors LLC increased its stake in Halozyme Therapeutics by 86.7% during the third quarter. Natixis Advisors LLC now owns 121,560 shares of the biopharmaceutical company’s stock worth $6,958,000 after acquiring an additional 56,461 shares during the last quarter. TrinityPoint Wealth LLC purchased a new stake in Halozyme Therapeutics in the third quarter valued at $214,000. Finally, Quest Partners LLC grew its holdings in shares of Halozyme Therapeutics by 1,386.0% during the 3rd quarter. Quest Partners LLC now owns 9,793 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 9,134 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock worth $1,754,451 over the last 90 days. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Stock Up 1.1 %

Halozyme Therapeutics stock opened at $62.95 on Tuesday. The firm has a market capitalization of $7.75 billion, a P/E ratio of 18.35, a P/E/G ratio of 0.42 and a beta of 1.32. The stock’s fifty day simple moving average is $57.05 and its 200-day simple moving average is $54.63. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $65.53. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Benchmark restated a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company dropped their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.